Clinical

The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.

Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer.

Two abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers analyzed biomarkers to predict progression, disease severity, and cognitive impairment in multiple sclerosis (MS).

Bone metastases can cause pain in patients with cancer, and 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting evaluated treating this pain.

Long-term use of ozanimod may be associated with improved cognitive speed and higher rates of no evidence of disease activity among patients with relapsing multiple sclerosis (MS), according to 2 new abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers.

Patients who switched from ozanimod HCI 0.5 mg or interferon β-1a to ozanimod HCI 1.0 mg in an open-label extension study experienced sustained reduction in their annualized relapse rate. Patients who continued on with the 1.0 mg dose also experienced a sustained reduction.